Alta Wealth Advisors LLC Invests $208,000 in Pfizer Inc. $PFE

Alta Wealth Advisors LLC bought a new position in Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,568 shares of the biopharmaceutical company’s stock, valued at approximately $208,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PFE. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the first quarter worth approximately $27,000. Bayforest Capital Ltd purchased a new stake in Pfizer during the 1st quarter valued at $28,000. North Capital Inc. purchased a new stake in Pfizer during the 1st quarter valued at $28,000. WPG Advisers LLC purchased a new stake in Pfizer during the 1st quarter valued at $35,000. Finally, Horizon Financial Services LLC purchased a new stake in Pfizer during the 1st quarter valued at $35,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on PFE shares. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Bank of America upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday. Finally, Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $28.41.

Pfizer Stock Up 1.1%

Shares of PFE stock opened at $27.37 on Friday. The company has a 50 day simple moving average of $24.67 and a two-hundred day simple moving average of $24.14. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market cap of $155.59 billion, a P/E ratio of 14.56, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.